Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 91 points (0.6%) at 15,720 as of Friday, Feb. 7, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 2,156 issues advancing vs. 753 declining with 162 unchanged. The Health Services industry currently sits up 0.6% versus the S&P 500, which is up 0.6%. Top gainers within the industry include St Jude Medical ( STJ), up 2.8%, Smith & Nephew ( SNN), up 2.2%, Boston Scientific ( BSX), up 2.1%, Thermo Fisher Scientific ( TMO), up 2.1% and Becton Dickinson ( BDX), up 1.6%. A company within the industry that fell today was Aetna ( AET), up 2.4%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Grifols ( GRFS) is one of the companies pushing the Health Services industry higher today. As of noon trading, Grifols is up $1.28 (3.4%) to $39.29 on light volume. Thus far, 208,051 shares of Grifols exchanged hands as compared to its average daily volume of 558,900 shares. The stock has ranged in price between $38.36-$39.43 after having opened the day at $38.36 as compared to the previous trading day's close of $38.01. Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, and Canada. Grifols has a market cap of $12.6 billion and is part of the health care sector. Shares are up 3.1% year-to-date as of the close of trading on Thursday. Currently there are 3 analysts who rate Grifols a buy, no analysts rate it a sell, and none rate it a hold. TheStreet Ratings rates Grifols as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and impressive record of earnings per share growth. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and generally higher debt management risk. Get the full Grifols Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.